NANOBODIES: STRUCTURE, MANUFACTURING, APPLICATION (REVIEW)
https://doi.org/10.33380/2305-2066-2019-8-1-14-22
Abstract
Introduction. Single-domain antibodies (nanobodies) are composed of the heavy-chain variable domain only. Compared to conventional immunoglobulins G (IgG) nanobodies have such qualities as: high bioavailability, ability to bind epitopes that are difficult to reach, high solubility and thermal stability, etc. Nanobodies can be easily manufactured in microorganisms (E. coli) to significantly save on cost.
Text. Goal of the paper consists of the description of structural and functional properties of nanobodies and its effective application.
Conclusion. Nanobodies can be used in many fields of medicine and biotechnology such as research, diagnostics and therapy of oncology, infectious, hematological, inflammatory, autoimmune and neurological diseases. They can also be easily modified using another nanobody, molecules or radioactive mark as necessary. Nanobodies have huge potential for applications in diagnostics, therapy and medicine.
About the Authors
A. V. Shatalova
Peoples’ Friendship University of Russia (RUDN University)
Russian Federation
Russian Federation
A. S. Yakubova
Peoples’ Friendship University of Russia (RUDN University)
Russian Federation
Russian Federation
V. V. Palimpsestov
Moscow Pedagogical State University
Russian Federation
Russian Federation
I. B. Esmagambetov
Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Vjatchanin A. S., Tillib S. V. Modifications of the phage display procedure to increase the efficiency of selection of antigen-binding domains of specific single-chain camel antibodies. Biotechnology. 2008; 4: 22–27 (In Russ.).
2. Man’ko V. M., Devrishov D. A. Veterinary immunology. Fundamentals: Textbook. M: Publishing «Agrovet». 2011; 752 р. (In Russ.).
3. Yarilin. A. A. Immunology: Textbook. M.: GEOTAR-Media. 2010; 752 р. (In Russ.).
4. Abbady A. Q. et al. Evaluation of a nanobody phage display library constructed from a Brucella-immunised camel. Veterinaty Immunology and Immunopathology. 2011; 142: 49–56.
5. Delanote V. et al. Ablynx. 2014. Challenging and intractable targets. Poster: Characterization of Anti-Kv1.3 Nanobodies and activity in Inflammatory model systems. Available at: http://www.ablynx.com/technology-innovation/nanobodies-competitive-features/ (accessed 20.03.18).
6. Ablynx. 2015. Press Releases: Ablynx Initiates Phase II SLE Study With Its Anti-IL–6R Nanobody, Partnered With Abbvie. Available at: http://www.ablynx.com/news/press-releases/?pyear=2015&lang=en (accessed 22.03.18)
7. Arbabi-Ghahroudi M., Tanha J., MacKenzie R. Prokaryotic expression of antibodies. Cancer Metastasis Rev. 2005; 24(4): 501–519.
8. Blanc M.R. et al. A one-step exclusion-binding procedure for the purification of functional heavy-chain and mammalian-type γ-globulins from camelid sera. Biotechnol. Appl. Biochem. 2009;54(4): 207–212.
9. Brissett R., Neil I. Goldsteine. The use of phage display peptide libraries for basic and translational research. Methods in Molecular Biology. 2007; 383: 203–213.
10. Chakravarty R. et al. Nanobody: The «Magic Bullet» for Molecular Imaging? Theranostics. 2014; 4(4): 386–398.
11. De Genst E. et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl. Acad. Sci. 2006; 103(12): 4586–4591.
12. Debets M.F. et al. Nanobody-functionalized polymersomes for tumorvessel targeting. Macromolecular Bioscience. 2013; 13: 938–945.
13. Desmyter A. et al. Camelid nanobodies: killing two birds with one stone. Current Opinion in Structural Biology. 2015; 32: 1 – 8.
14. Detalle L. et al. Generation and characterisation of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrobal Agents and Chemotherapy. 2015; 60: 6–13.
15. Ellen R. Goldman et al. Enhancing Stability of Camelid and Shark Single Domain Antibodies: An Overview. Front Immunol. 2017; 8: 865.
16. Estell D. et al. Adapting industry practices for the rapid, largescale manufacture of pharmaceutical proteins. The Bridge. 2006; 36(3):39–44.
17. Gonzalez-Sapienza G. et al. Single-Domain Antibodies As Versatile Affinity Reagents for Analytical and Diagnostic Applications. Front Immunol. 2017; 8: 977.
18. Hamers-Casterman C. et al. Naturally occurring antibodies devoid of light chains. Nature. 1993; 363: 446–448.
19. Harmsen M. M., De Haard H. J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 2007; 77(1): 13–22.
20. Harmsen M.M. et al. Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol. Immunol. 2000; 37(10): 579–590.
21. Hassanzadeh-Ghassabeh G. et al. Nanobodies and their potential applications. Nanomedicine (Lond). 2013; 8(6): 1013–1026.
22. Hu Y., Liu C., Muyldermans S.Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy. Frontiers in immunology. 2017; 8: 1442.
23. Lauwereys M., Ghahroudi M. A. et al. Potent enzyme inhibitors derived from dromedary heavychain antibodies. EMBO J. 1998; 17: 3512–3520.
24. Maass D. R. et al. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J. Immunol. Methods. 2007; 324: 13–25.
25. Mullard A. 2014 FDA drug approvals. Nature Reviews Drug Discovery. 2015; 14: 77–81.
26. Muyldermans S. et al. Camelid immunoglobulins and nanobody technology. Vet. Immunol. Immunopathol. 2009; 128: 178–183.
27. Muyldernans S. Nanobodies: Natural Single-Domain Antibodies. Annu.Rev.Biochem. 2013. V.; 82: 17.1–17.23.
28. Nguen V. K. et al. Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. 2000; 19(5): 921–930.
29. Nguyen V. K. et al. The Specific Variable Domain of Camel heavychain antibodies is encoded in the germline. J. Mol. Biol. 1998; 275(3): 413–418.
30. Nguyen V. K., Desmyter A., Muyldermans S. Functional heavy-chain antibodies in Camelidae. Adv. Immunol. 2001; 79: 261–296.
31. Nuttall S. D. et al. Isolation of a new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol. Immunol. 2001; 38(4): 313–326.
32. Oriol Sunyer J. Evolutionary and Functional Relationships of B Cells from Fish and Mammals: Insights into their Novel Roles in Phagocytosis and Presentation of Particulate Antigen. Infect Disord Drug Targets. 2012; 12(3): 200–212.
33. Pardon E. A. et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protocols. 2014; 9(3): 674–693.
34. Pleiner T., Bates M. Nanobodies: site-specific labeling for superresolution imaging, rapid epitope-mapping and native protein complex isolation. Elife. 2015; 4.
35. R. van der Linden et al. Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. J. Immunol. Methods. 2000; 240(1-2); 185–195.
36. Rahbarizadeh F. et al. Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Mol. Immunol. 2006; 43(5): 426–435.
37. Ryman J. T., Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics and System Pharmacology. 2017; 6(9): 576–588.
38. Saerens D. et al. Antibody fragments as probe in biosensor development. Sensors (Basel). 2008; 8(8): 4669–4686.
39. Seligmann M. et al. Heavy chain diseases: current findings and concepts. Immunological Rev. 1979; 48: 145–167.
40. Sharkey R. M., Goldenberg D. M. Cancer radioimmunotherapy. Immunotherapy. 2011; 3: 349–370.
41. Steeland S. et al. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016; 21(7): 1076–1113.
42. Tilib S. V. «Camel Nanoantibody» is an Efficient Tool for Research, Diagnostics and Therapy. Molecular Biology. 2011; 45(1): 66–73.
43. Van Heeke G. et al. Nanobodies as inhaled biotherapeutics for lung diseases. Pharmacol Ther. 2017; 169: 47–56.
44. Woolven B. P. et al. The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation. Immunogenetics. 1999; 50(1-2): 98–101.
45. Yan J. et al. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library. J. Nanobiotechnology. 2015; 6: 13–33.
46. Yardehnavi N. et al. A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation. Faseb J. 2014; 28(9): 4004–4014.
47. Zou T. et al. Nanobody-functionalized PEG-b-PCL polymersomes and their targeting study. Journal of Biotechnology. 2015; 214: 147–155.
Review
For citations:
Shatalova A.V., Yakubova A.S., Palimpsestov V.V., Esmagambetov I.B. NANOBODIES: STRUCTURE, MANUFACTURING, APPLICATION (REVIEW). Drug development & registration. 2019;8(1):14-22. (In Russ.) https://doi.org/10.33380/2305-2066-2019-8-1-14-22
Views:
3503
Email this article 